CMS has pro­posed a pol­i­cy change that clar­i­fies its stance on how prod­ucts are grouped to­geth­er for Medicare ne­go­ti­a­tions.

Un­der the In­fla­tion Re­duc­tion Act, bi­o­log­ics...

With a for­mi­da­ble new com­peti­tor set to en­ter the orex­in de­vel­op­ment race, Take­da is out with new da­ta it hopes re­in­forces mar­ket-lead­ing po­ten­tial.

The ad­di­tion­al...

PHILADEL­PHIA– Fol­low­ing the re­cent de­par­tures of FDA Com­mis­sion­er Mar­ty Makary and both of his cen­ter di­rec­tors for drugs and bi­o­log­ics, the Trump ad­min­is­tra­tion will...

Mer­ck’s Welireg and Keytru­da com­bi­na­tion won ap­proval as an ad­ju­vant treat­ment for kid­ney can­cer pa­tients af­ter surgery to re­move all or part of the or­gan...

Eli Lil­ly made a push in blood can­cer at this year’s Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion meet­ing in Stock­holm over the week­end.

The drug­mak­er pre­sent­ed da­ta for...

Plus news about Sanofi, Phar­ma­Mar, Jazz, Rhythm Phar­ma­ceu­ti­cals, Spyre and Zymeworks

🇨🇳 An­oth­er obe­si&s